Search
for
Sort by
Research
720-750 / 1000+ results research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
research Screening of Tyrosinase, Xanthine Oxidase, and α-Glucosidase Inhibitors from Polygoni Cuspidati Rhizoma et Radix by Ultrafiltration and HPLC Analysis
Polygoni Cuspidati Rhizoma et Radix contains compounds that inhibit certain enzymes.
research Lichenoid dermatitis from interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV
A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens against E2F1-Driven Melanoma Progression
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
This study evaluated the 28-week effectiveness and safety of tralokinumab in 84 adult patients with moderate-to-severe atopic dermatitis (AD). The treatment significantly improved clinical outcomes, with 75.8% achieving an Eczema Area and Severity Index (EASI) of ≤7 and 51.4% achieving a numerical rating scale (NRS) for pruritus of ≤4. Serum proteins associated with disease severity decreased, and total IgE levels significantly decreased in dupilumab-naïve patients. However, 27.4% of patients discontinued treatment due to adverse events or ineffectiveness, with hair loss being the most common reason for discontinuation. Overall, tralokinumab proved effective for both dupilumab-naïve and non-naïve patients, with clinical improvements supported by biological data.
research Review of the Literature: Topical JAK Inhibitors Showing Promise for Hair Loss!
Topical JAK inhibitors may help treat hair loss.
research Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Thyroid receptor agonists for the treatment of androgenetic alopecia
Thyroid receptor agonists may treat male pattern baldness without harmful side effects.
research Treatment of longstanding alopecia areata universalis of the eyebrows/facial hair with oral and topical tofacitinib
Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
research Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
research Oral Tofacitinib in Refractory Pediatric Alopecia Areata
Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Epidermal γδ T cells, CD8 T cells and macrophages are increased in number in alopecia areata and express BST2 as part of an interferon-driven antiviral gene signature
In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
Upadacitinib is effective and safe for treating severe alopecia areata in teens.
research Analysis of the function of ADAM17 in iRhom2 curly-bare and tylosis with esophageal cancer mutant mice
Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research NEW PROPRIETARY BRANDS: Cefaclor monohydrate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research Anti-acne drugs in phase 1 and 2 clinical trials
New anti-acne medications are being tested to offer alternatives to current treatments.
research A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Komplet remission ved behandling med JAK-hæmmer hos en patient med alopeciatotalis
Tofacitinib helped a man with alopecia totalis regrow all his hair.